Is CRISPR Therapeutics Stock Poised to Soar Nearly 30%?
Gene-editing leader CRISPR Therapeutics (NASDAQ: CRSP) has generated sizzling returns for investors over the last 12 months. But one analyst thinks the biotech stock can go much higher. In this Motley Fool Live video, recorded on March 10, Fool.com contributors Keith Speights and Brian Orelli discuss whether or not CRISPR Therapeutics can soar nearly 30% from current levels as one top analyst predicts.
Source Fool.com